(+)-3,5-Diisopropyl-2-(1-hydroxyethyl)-6-propyl-4'-fluoro-1,1'-biphenyl | 202855-56-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (+)-3,5-Diisopropyl-2-(1-hydroxyethyl)-6-propyl-4'-fluoro-1,1'-biphenyl
• 英文别名: 2-(4-fluoro-3,5-diisopropyl-6-propylbiphenyl-2-yl)ethanol；1-[2-(4-Fluorophenyl)-4,6-di(propan-2-yl)-3-propylphenyl]ethanol
• CAS: 202855-56-9
• 化学式: C₂₃H₃₁FO
• 分子量: 342.497
• InChiKey: VDTWKXAPIQBOMO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.8
• 重原子数：
  25
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.48
• 拓扑面积：
  20.2
• 氢给体数：
  1
• 氢受体数：
  2

文献信息

• 3-(4-AMINOPHENYL)-2-FURANCARBOXYLIC ACID DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF
  申请人：Fujii Akihito

  公开号：US20120059012A1

  公开（公告）日：2012-03-08

  Disclosed is a compound represented by Formula (I) or a pharmaceutically acceptable salt thereof: wherein R 1 is 1: a C 3-8 cycloalkyl C 1-4 alkyl group, 2: a C 7-14 aralkyl group, in which the aryl moiety thereof is optionally substituted with the same or different 1 to 3 groups selected from the group consisting of: (a) halogen, (b) C 1-4 alkyl, which is optionally substituted with 1 to 3 fluorine atoms, (c) C 1-4 alkoxy, which is optionally substituted with 1 to 3 fluorine atoms, and (d) C 1-4 alkylcarbonyl, which is optionally substituted with C 1-4 alkoxy, 3: a five- to ten-membered heteroaryl-C 1-4 alkyl group, in which the heteroaryl moiety thereof is optionally substituted with the same or different 1 to 3 groups selected from the group consisting of: (a) halogen, and (b) C 1-4 alkyl, or 4: a C 6-10 aryl C 2-6 alkenyl group; and R 2 is a cyano group or a nitro group.

  揭示了由化学式（I）表示的化合物或其药学上可接受的盐：其中R1是1：C3-8环烷基C1-4烷基基团，2：C7-14芳基烷基基团，其中其芳基部分可选择性地取代为来自以下组成的1至3个相同或不同的基团：(a)卤素，(b)C1-4烷基，可选择性地取代为1至3个氟原子，(c)C1-4烷氧基，可选择性地取代为1至3个氟原子，和(d)C1-4烷基羰基，可选择性地取代为C1-4烷氧基，3：五元至十元杂芳基-C1-4烷基基团，其中其杂芳基部分可选择性地取代为来自以下组成的1至3个相同或不同的基团：(a)卤素，和(b)C1-4烷基，或4：C6-10芳基C2-6烯基基团；和R2是氰基或硝基基团。
• SUBSTITUTED PYRIDINES AND BIPHENYLS AS ANTI-HYPERCHOLESTERINEMIC, ANTI-HYPERLIPOPROTEINEMIC AND ANTI-HYPERGLYCEMIC AGENTS
  申请人：Bayer Corporation

  公开号：EP0934274A1

  公开（公告）日：1999-08-11
• Combination treatment for diabetes mellitus
  申请人：Klein Thomas

  公开号：US20100179131A1

  公开（公告）日：2010-07-15

  The invention relates to combinations of (2R,4aR,10bR)-6-(2,6-Dimethoxy-pyridin-3-yl)-9-ethoxy-8-methoxy-1,2,3,4,4a,10b-hexahydrophenanthridine-2-ol with other active compounds for the treatment of diabetes mellitus type 2 and/or type 1.
• COMBINATION TREATMENT FOR DIABETES MELLITUS
  申请人：KLEIN Thomas

  公开号：US20120129817A1

  公开（公告）日：2012-05-24

  The subject matter of this application is directed to combinations of (2R,4aR,10bR)-6-(2,6-Dimethoxy-pyridin-3-yl)-9-ethoxy-8-methoxy-1,2,3,4,4a,10b-hexahydrophenanthridin-2-ol with other active compounds for the treatment of diabetes mellitus type 2 and/or type 1.
• ANTI-GLUCAGON ANTIBODIES AND USES THEREOF
  申请人：Eli Lilly and Company

  公开号：US20140335096A1

  公开（公告）日：2014-11-13

  Provided are monoclonal antibodies, or antigen-binding fragments thereof, that bind to glucagon. These antibodies are useful in immunoassays of glucagon levels, and/or in vivo, ex vivo or in vitro immunochemical and other imaging methods for detecting glucagon levels, and for diagnostic, prognostic and predictive purposes, and for optimizing therapeutic regimens in patients in which glucagon signaling is implicated in pathogenesis.